Latest filing published 23 Dec 2025 for MAIA Biotechnology, Inc., €60k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Stan Smith appears in our data through filings on MAIA Biotechnology, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 1 August 2022 to 22 December 2025, the count stands at 35 filings.
On the market, this insider has only ever bought: 35 purchases, €2.5M in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €10k. Clusters matter here: 28 out of 33 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The newest entry dates from 12 January 2026: an open-market purchase of €9,929, in MAIA Biotechnology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 34 declarations